H. Christian Fibiger

Biography

  Dr. H. Christian Fibiger, also known as Chris, Ph.D., serves as Chief Scientific Officer of HLS Therapeutics Inc. Dr. Fibiger has been a Scientific Advisor of ImStar Therapeutics Inc., since June 6, 2016. He is a Consultant to The Life Sciences Industry. Dr. Fibiger has significant experience across a broad range of world leading companies. He served as Chief Scientific Officer and Senior Vice President of Biovail Corporation and its subsidiary Valeant International Bermuda (alternatively Biovail Laboratories International SRL (BLS) and Valeant International (Barbados) SRL) since November 24, 2008. Dr. Fibiger was a Consultant of iCo Therapeutics Inc. He served as a Vice President and Global Therapeutic Area Head for Neuroscience Research of Amgen Inc., from October 16, 2003 to July 2007. He was responsible for Amgen Inc.'s worldwide internal Neuroscience discovery efforts, as well as the evaluation and implementation of collaborative efforts, alliances and licensing agreements with external partners. Prior to Amgen Inc., he served as Vice President of Neuroscience Discovery Research & Clinical Investigation and Vice President of Lilly Research Laboratories for Europe at Eli Lilly and Company. He joined Eli Lilly in 1998. Prior to this, he served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at UBC. From 1972 to 1998, Professor and Head of the Division of Neuroscience at University of British Columbia. Dr. Fibiger served as the Chief Scientific Officer of MedGenesis Therapeutix Inc. He served as Chief Scientific Officer and Senior Vice President of Biovail Laboratories International SRL. He serves as the Chairman of External Advisory Board at Biovail Corporation. He serves as Chairman of External Advisory Board at Valeant Pharmaceuticals International, Inc. He has been Director of ImStar Therapeutics Inc., since June 6, 2016. He serves as a Director of MedGenesis Therapeutix Inc. He served as an Independent Director at biOasis Technologies Inc. since February 12, 2010 until September 21, 2017. He served as a Member of Medical Advisory Board and Director for Orasi Medical, Inc. He served as a Director of iCo Therapeutics Inc., from June 27, 2008 to June 5, 2009 and Sirius Genomics Inc., from November 2008 to June 2009. Dr. Fibiger has been a member of a variety of national and international scientific advisory boards including the National Institute of Mental Health (USA), the Canadian Psychiatric Research Foundation (Canada), the Medical Research Council (Canada), the Human Frontiers Science Program (International) and the National Alliance for Research on Schizophrenia and Affective Disorders (USA). He has authored or co-authored over 400 publications and has made numerous contributions to neuroscience research. He received numerous honours for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research and is a Fellow of the American College of Neuropsychopharmacology. He is a highly experienced and recognized scientist. Dr. Fibiger holds a B.Sc. in Chemistry and Psychology from the University of Victoria, British Columbia, Canada, in 1966 and a Ph.D. in Psychopharmacology from Princeton University, Princeton, N.J. in 1970.  

Research Interest

 chemistry, psychology